The Cooper Companies, Inc. · COO · FY2025 Q1 · Calendar Q1 2025

Cooper Companies: MyDay momentum supports a higher EPS floor

The quarter supports a constructive but qualified view: demand for MyDay and MySite, added capacity, and private-label growth provide operating support, while China weakness, inventory risks, competition, and currency remain important offsets.

What drove COO's -6.6% move after FY2025 Q1 earnings?

Research this report with FN2. Free to start; review your question before sending.

Reported After market closeNASDAQHealthcare $11.10B market cap
80quality score

Earnings scorecard

Reported versus consensus
Reported EPS — Consensus $0.92
EPS surprise — Reported versus consensus
Reported revenue — Consensus $981.3M
Revenue surprise — Reported versus consensus
Check the math in the surprise calculator >

Market reaction

event-close to next-session close
Stock move -6.6% Event window
SPY move +0.6% Same window
Abnormal move -7.1% Stock minus SPY
Volume 3.0× Versus trailing sessions
Subsequent drift -13.2% Up to 20 sessions
COOSPY benchmark

Ask FN2 about COO FY2025 Q1

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with the prior-quarter analysis, guidance sentiment moved from maintained to raised: full-year revenue guidance stayed unchanged, but the lower end of non-GAAP EPS guidance increased. MyDay capacity was ahead of schedule, and management emphasized private-label growth and the Sight Glass joint venture.

Guidance delta

Full-year revenue guidance was unchanged, while the lower end of non-GAAP EPS guidance was raised.

Key takeaways

  • Q1 revenue grew 4% year over year to $965 million, with non-GAAP EPS of $0.92 and free cash flow of $101 million.
  • MyDay and MySite were identified as important growth drivers, with manufacturing capacity expansion supporting availability.
  • Private-label partnerships remain a long-term growth pillar and are expected to grow slightly faster than branded products this year.
  • Management highlighted China weakness, inventory risks, currency volatility, and potential IUD and lens competition.

Management priorities

  • Expand MyDay manufacturing capacity and launch products in additional international markets.
  • Develop MyDay MySite and broaden myopia-management initiatives.
  • Invest in fertility and surgical product pipelines.
  • Grow private-label partnerships and evaluate joint-venture opportunities.

Follow COO with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
COO REVENUE earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $925M Q4 '23 actual $927M, beat Q1 '24 estimate $916M Q1 '24 actual $932M, beat Q2 '24 estimate $948M Q2 '24 actual $943M, miss Q3 '24 estimate $997M Q3 '24 actual $1B, beat Q3 '25 estimate $1B Q3 '25 actual $1B, miss Q4 '25 estimate $1B Q4 '25 actual $1B, beat Q1 '26 estimate $1B Q1 '26 actual $1B, match Q2 '26 estimate $1B Q2 '26 actual $1B, beat Q3 '26 estimate $1B Q3 '26 actual $1B, miss Q4 '26 estimate $1B Q1 '27 estimate $1B Q2 '27 estimate $1B Q3 '27 estimate $1B
Show less

Analyst Consensus ?

ConsensusHold26 ratings
Bullish1350.0%
Neutral1246.2%
Bearish13.8%

1 unmapped firm rating excluded from the percentages.

Analyst 52W Price Targets

$58.88Current
$59Low
$92.69Average
$368High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Needham Buy BuyMaintainSep 15, 2026
Mizuho Outperform OutperformMaintainSep 11, 2026
William Blair Market Perform OutperformDowngradeSep 10, 2026
Wells Fargo Equal Weight Equal WeightMaintainSep 10, 2026
UBS Neutral NeutralMaintainSep 10, 2026
Show 22 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $58.88. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BarclaysAnalyst unavailable$60$56.43 +1.9%Oct 6, 2026
Mizuho SecuritiesAnthony Petrone$75$55.22 +27.4%Sep 10, 2026
UBSAnalyst unavailable$66$63.48 +12.1%Sep 10, 2026
NeedhamDavid Saxon$73$63.48 +24.0%Sep 10, 2026
Wells FargoAnalyst unavailable$61$63.48 +3.6%Sep 10, 2026
See 36 more

Track every rating change on COO the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue.…

Historical context

All COO earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the COO recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2025-02-20T00:00:54.474485+00:00
  3. Polygon adjusted daily market bars · 2026-10-05T15:40:41.599905+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-05T15:40:41.596938+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-05. For educational purposes only; not investment advice.